Summary
Lazaroids (or 21-aminosteroids) are potent lipid peroxidation inhibitors and are more potent antioxidants than steroids which have been shown to suppress tumor proliferation. The effects of two lazaroid compounds (U-75389G and U-83836E) were tested on the proliferation of a human brain astrocytoma cell line U-373 MG. Both lazaroids had dose-dependent growth-inhibitory effects on the proliferation of U-373 MG. For purposes of comparison, two steroids (methylprednisolone and dexamethasone) and a highly potent antioxidant (alpha-tocopherol) were tested under similar experimental conditions and were found to have antiproliferative effects as well, although at higher dose ranges. As cell growth-inhibitors, lazaroids are more effective than alpha-tocopherol while they are advantageous over glucocorticoids for their actions are devoid of the usual glucocorticoid side-effects.
Similar content being viewed by others
References
Braughler JM, Pregenzer JF: The 21-aminosteroid inhibitors of lipid peroxidation: reactions with lipid peroxyl and phenoxy radicals. Free Radic Biol Med 7:125–130,1989
Hall DH, McCall JM, Chase RL, Yonkers PA, Braughler JM: A nonglucocorticoid steroid analog of methylprednisolone duplicates its high-dose pharmacology in models of central nervous system trauma and neuronal membrane damage. J Pharmacol Exp Ther 242:137–142,1987
Braughler JM, Burton PS, Chase RL, Prezenger JF, Jacobsen EJ, Vandoornik FJ, Tustin JM, Ayer DE, Bundy GL: Novel inhibitors of iron-dependent chelators as inhibitors of iron-dependent lipid peroxidation. Biochem Pharmacol 37: 3853–3860,1988
Halliwell B, Gutteridge JMC: Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 219:1–14,1984
Yu BP: Cellular defenses against damage from reactive oxygen species. Physiol Rev 74:139–162,1994
Nagy K, Pasti G, Bene L, Nagy IZS: Induction of granulocytic maturation in HL-60 human leukemia cells by free radicals: a hypothesis of cell differentiation involving hydroxyl radicals. Free Radic Res Commun 19:1–15,1993
Kimura M, Maeda K, Hayashi S: Cytosolic calcium increase in coronary endothelial cells after H2O2 exposure and the inhibitory effect of U-78517F. Br J Pharmacol 107:488–493, 1992
Doan TN, Gentry DL, Taylor AA, Elliot SJ: Hydrogen peroxide activates agonist-sensitive Ca2+-flux pathways in canine venous endothelial cells. Biochem J 297:209–215,1994
Rohn TT, Hinds TR, Vincenzi FF: Ion transport ATPases as targets for free radical damage. Biochem Pharmacol 46: 525–534,1993
Taker MM, Garcia JGN, Natarajan V: Hydroperoxide-induced diacylglycerol formation and protein kinase C activation in vascular endothelial cells. Arch Biochem Biophys 303:260–266,1993
Rao GN, Lassegue B, Griendling KK, Alexander RW, Berk BC: Hydrogen peroxide-induced c-fos expression is mediated by arachidonic acid: role of protein kinase C. Nucl Acids Res 21:1259–1263,1993
Rao GN, Lassegue B, Griendling KK, Alexander RW, Berk BC: Hydrogen peroxide stimulates transcription of c-jun in vascular smooth muscle cells: role of arachidonic acid. Oncogene 8:2759–2764,1993
Nakamura Y, Gindhart TD, Winterstein D, Seed JL, Colburn NH: Early superoxide dismutase-sensitive event promotes neoplastic transformation in mouse epidermal JB6 cells. Carcinogenesis 9:203–207,1988
Ozer NK, Palozza P, Boscoboinik D, Azzi A: d-α-Tocophe-rol inhibits low density lipoprotein induced proliferation and protein kinase C activity in vascular smooth muscle cells. FEBS Lett 322:307–310,1993
Tutton PJM, Barla DH: Steroid hormones as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells. Anticancer Res 8:451–456,1988
Lee YS, Wurster RD: Dual effects of estrogen and antiestrogens on the growth of SK-N-MC human neuroblastoma cells. Cancer Lett 86:119–125,1994
Ryungsoon SK, Zabornik CLF, Begleiter A, LaBella FS: Antiproliferative properties of aminosteroid antioxidants on cultured cancer cells. Cancer Lett 64:61–66,1992
Hall ED, Yonkers PA, Horan KL, Braughler JM: Correlation between attenuation of posttraumatic spinal cord ischemia and preservation of vitamin E by the 21-aminosteroid U-740067: evidence for an in vivo antioxidant action. J Neurotrauma 6:169–176,1989
Braughler JM, Prezenger JF, Chase RL, Duncan LA, Jacobsen EJ, McCall JM: Novel 21-aminosteroids as potent inhibitors of iron-dependent lipid peroxidation. J Biol Chem 262: 10438–10440,1987
Lee YS, Sayeed MM, Wurster RD: Inhibition by Ca2+ channel antagonists of the cell growth and intracellular Ca2+ mobilization in human brain tumor cells. Mol Chem Neuropathol 22:81–95,1994
Ashendel CL, Minor PL: Mechanism of phorbol ester activation of calcium-activated, phospholipid-dependent protein kinase. Carcinogenesis 7:517–521,1986
Audos KL, Guillot FL, Braughler JM: Evidence for 21-aminosteroid association with the hydrophobic domains of brain microvessel endothelial cells. Free Radic Biol Med 11: 361–371,1991
Braughler JM, Chase RL, Neff GL, Day JS, Yonkers PA, Hall ED, Sethy VH, Lahti RA: A new 21-aminosteroid antioxidant lacking glucocorticoid activity stimulates ACTH se cretion and blocks arachidonic acid release from mouse pituitary (AtT-20) cells. J Pharmacol Exp Ther 244:423–427, 1988
Tarboletti G, Perin L, Botazzi B, Mantovani A, Giavazzi R, Salmona M: Membrane fluidity affects tumor-cell motility, invasion and lung- colonizing potential. Int J Cancer 44: 707–713,1989
Tomohiro Y, Obata Y, Ishikawa G, Ichikawa T: Enhancing effect of dietary iron on lung tumorigenesis. Cancer Lett 76: 57–62,1994
Singh JP, Bonin PD: Inhibition of proliferation of fibroblasts by lazaroids (21-aminosteroids). Life Sci 49:2053–2058,1991
Mattanna A, Bennardini F, Juliano C, Picci V, Marceddu S, Sciola L, Pippia P, Franconi F: Cytotoxicity of lazaroid U-754126E in human epithelial cell line (WISH). Biochem Pharmacol 48:259–265,1994
Kennedy AR, Troll W, Little B: Role of free radicals in the initiation and promotion of radiation transformation in vitro. Carcinogenesis 5:510: 1213–18
Fleishaker JC, Hulst LK, Peters GR: Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5–10 days in healthy volunteers. Int J Clin Pharmacol and Therapeutics 32(5): 223–230,1994
Fleishaker JC, Peters GR, Cathhurt KS: Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate. a 21-aminosteroid free radical scavenger: I. Single-dose administration. J Clin Pharmacol 33:175–181,1993
Flesishaker JC, Peters GR, Cathhurt KS, Steenwyck RC: Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration. J Clin Pharmacol 33:182–190, 1993
Haley EC Jr, Kassell NF, Alves WM, Weir BK, Hansen CA: Phase II trial of tirilazad in aneurysmal subarachinoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 82(5):786–790,1995
Anonymous: Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 25(2):418–423, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arora, P., Lee, Y.S., Origitano, T.C. et al. Lazaroids inhibit proliferation of cultured human astrocytoma cells. J Neuro-Oncol 29, 143–148 (1996). https://doi.org/10.1007/BF00182137
Issue Date:
DOI: https://doi.org/10.1007/BF00182137